- Sustained down-regulation of two independent secreted liver gene products in blood serum was observed for over 200 days
- Serum levels of TTR protein were reduced by approximately 70%
- In the cross-controlled experimental cohort, serum levels of PCSK9 protein were reduced by approximately 55%
- Target levels in the groups treated with a guide RNA (gRNA) directed to a different gene were comparable to those of untreated animals
What the broker says...
The shares were changing hands unchanged at 114.5p, valuing the business at £82mln. The broker Canaccord Genuity reckons the stock is worth 249p.
Analyst Howard Miller said: “This makes Silence one of the few companies to have demonstrated effective CRISPR-/Cas9 gene editing through in vivo delivery, compared with the traditional ex vivo approach.
“The LNPs have been shown to be suitable for effective delivery of large cargos such as RNA CRISPR-Cas9 components, opening up partnering discussions in this field.”